As of 2025-05-16, the EV/EBITDA ratio of Tonix Pharmaceuticals Holding Corp (TNXP) is -1.74. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TNXP's latest enterprise value is 117.87 mil USD. TNXP's TTM EBITDA according to its financial statements is -67.66 mil USD. Dividing these 2 quantities gives us the above TNXP EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.0x - 13.3x | 13.2x |
| Forward P/E multiples | 16.6x - 30.9x | 19.0x |
| Fair Price | (137.77) - (108.42) | (133.60) |
| Upside | -592.0% - -487.2% | -577.1% |
| Date | EV/EBITDA |
| 2025-05-15 | -1.20 |
| 2025-05-14 | -1.09 |
| 2025-05-13 | -0.88 |
| 2025-05-12 | -0.77 |
| 2025-05-09 | -0.73 |
| 2025-05-08 | -0.74 |
| 2025-05-07 | -0.76 |
| 2025-05-06 | -0.74 |
| 2025-05-05 | -0.81 |
| 2025-05-02 | -0.86 |
| 2025-05-01 | -0.64 |
| 2025-04-30 | -0.64 |
| 2025-04-29 | -0.57 |
| 2025-04-28 | -0.53 |
| 2025-04-25 | -0.62 |
| 2025-04-24 | -0.55 |
| 2025-04-23 | -0.53 |
| 2025-04-22 | -0.30 |
| 2025-04-21 | -0.30 |
| 2025-04-17 | -0.39 |
| 2025-04-16 | -0.40 |
| 2025-04-15 | -0.53 |
| 2025-04-14 | -0.43 |
| 2025-04-11 | -0.51 |
| 2025-04-10 | -0.56 |
| 2025-04-09 | -0.63 |
| 2025-04-08 | -0.84 |
| 2025-04-07 | -0.62 |
| 2025-04-04 | -0.38 |
| 2025-04-03 | -0.58 |
| 2025-04-02 | -0.57 |
| 2025-04-01 | -0.58 |
| 2025-03-31 | -0.62 |
| 2025-03-28 | -0.88 |
| 2025-03-27 | -1.60 |
| 2025-03-26 | -1.83 |
| 2025-03-25 | -1.94 |
| 2025-03-24 | -2.02 |
| 2025-03-21 | -1.19 |
| 2025-03-20 | -0.66 |
| 2025-03-19 | -0.47 |
| 2025-03-18 | -0.92 |
| 2025-03-17 | -0.45 |
| 2025-03-14 | -0.31 |
| 2025-03-13 | -0.16 |
| 2025-03-12 | -0.13 |
| 2025-03-11 | -0.16 |
| 2025-03-10 | -0.14 |
| 2025-03-07 | -0.09 |
| 2025-03-06 | -0.27 |